Valeant Announces Leadership Changes

Valeant Pharmaceuticals announced appointments to the dermatology leadership team of Michael McMyne as vice president of Sales, and Stacey Williams as vice president of Marketing. Additionally, the company announced Lainie Keller has joined as vice president of Corporate Communications.

In his new role, McMyne will be responsible for dermatology sales. He most recently served as vice president of operations for Merz North America. While at Merz, McMyne launched a channel marketing team and led the integration of two key acquisitions into the company's dermatology portfolio. Prior to that, McMyne served in various commercial roles at Medicis Pharmaceuticals, including associate director of sales for dermatology.

Williams has joined Valeant to oversee the marketing strategy and execution of the dermatology organization. She has diverse experience in the commercial health care segment that includes medical devices, pharmaceuticals, R&D and manufacturing. Prior to this new role, she was senior marketing director for Merz North America, where she led strategic direction and tactical execution for a neuroscience portfolio that included biologic, pharmaceutical and medical device products.

"Michael and Stacey each have a proven track record of results, execution and strategic agility within specialty pharmaceuticals and more specifically, the specialty of dermatology," Bill Humphries, executive vice president and company group chairman, Valeant Dermatology said. We are committed to securing the company's future in the dermatology space, and I look forward to working with these talented leaders to realize the full potential of this key business for Valeant."

In a newly created role, Keller will be responsible for executing external corporate communications and media relations strategies for Valeant. She joined the company from Merck, where she most recently served as a director of corporate media relations, overseeing corporate, financial, litigation and policy communications. During her 10 years at Merck, she also served as a director of communications for various product portfolios.

"Communicating accurately and transparently is one of our highest priorities," said Scott Hirsch, senior vice president, Business Strategy and Communications, Valeant. "Lainie's experience in developing and leading successful, strategic communications programs on behalf of global pharmaceutical and health care companies will be invaluable as we continue to transform Valeant."